In order to investigate whether the aberrantly induced signaling observed in CLL cells could be reversed to normal levels, anti-IgM induced Akt (pS473) signaling was targeted using a range of concentrations of the PI3Kδ inhibitor idelalisib (Figure 4D). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.